Nonexudative Macular Neovascularization in Age-Related Macular Degeneration - Poll - MDSpire

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • By

  • Sridevi Thottarath

  • Sarega Gurudas

  • Syed Kubravi

  • Dimitrios Kazantzis

  • Ayse Merve Keskin

  • Sobha Sivaprasad

  • EYENEON Study Group

  • Benjamin Burton

  • Geeta Menon

  • Manju Chandran

  • Ian Pearce

  • Savita Madhusudhan

  • Anna Grabowska

  • Faruque Ghanchi

  • James Talks

  • Richard Gale

  • Martin McKibbin

  • Ajay Kotagiri

  • Niro Narendran

  • Afsar Jafree

  • Saad Younis

  • Claire Bailey

  • Priya Prakash

  • Christiana Dinah

  • Louise Downey

  • Andrew Lottery

  • Paritosh Shah

  • Romi Chhabra

  • Narendra Dhingra

  • Indra Dias

  • Mary Freeman

  • Daren Hanumunthadu

  • May 1, 2026

  • 0 min

Share

Original Source(s)

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

  • by Sridevi Thottarath, Sarega Gurudas, Syed Kubravi, Dimitrios Kazantzis, Ayse Merve Keskin, Sobha Sivaprasad, EYENEON Study Group, Benjamin Burton, Geeta Menon, Manju Chandran, Ian Pearce, Savita Madhusudhan, Anna Grabowska, Faruque Ghanchi, James Talks, Richard Gale, Martin McKibbin, Ajay Kotagiri, Niro Narendran, Afsar Jafree, Saad Younis, Claire Bailey, Priya Prakash, Christiana Dinah, Louise Downey, Andrew Lottery, Paritosh Shah, Romi Chhabra, Narendra Dhingra, Indra Dias, Mary Freeman, Daren Hanumunthadu

  • May 1, 2026

Related Content

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

Educating Patients on IOL Options Is Key

Stone Oak Ophthalmology Center strives to provide an environment in which patients fully understand their options and feel confident with their IOL choices.

Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

  • May 1, 2025

  • 3 min